Last reviewed · How we verify

NCT06968468: RT-ALS

Resiliency Intervention for Patients With ALS and Their Care-Partners

Not yet recruiting NA Last updated 17 November 2025
What this trial tests

NA trial testing Resilient Together ALS in Amyotrophic Lateral Sclerosis (ALS) in 20 participants. Not yet recruiting.

Timeline
13 May 2026
Primary endpoint
13 February 2027
28 February 2027

Quick facts

Lead sponsorMassachusetts General Hospital
PhaseNA
StatusNot yet recruiting
Study typeINTERVENTIONAL
Allocationna
Designsingle group
Maskingnone
Primary purposetreatment
Enrollment20
Start date13 May 2026
Primary completion13 February 2027
Estimated completion28 February 2027
Sites1 location across United States

Drugs / interventions tested

Conditions studied

Sponsor

Massachusetts General Hospital

Who can join

18 and older, any sex, with Amyotrophic Lateral Sclerosis (ALS) or Emotional Distress. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The purpose of this study is to pilot a resiliency and coping intervention for persons recently diagnosed with Amyotrophic Lateral Sclerosis (ALS) and their primary informal caregivers. The data investigators gather in this study will be used to further refine our intervention.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Amyotrophic Lateral Sclerosis (ALS)

Currently open trials in the same condition.

Other Massachusetts General Hospital trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06968468.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing